Hematopoietic Stem Cell Therapy for Patients With Refractory Myasthenia Gravis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00424489
Recruitment Status : Terminated (No participants enrolled for more than two years. No plan to continue study.)
First Posted : January 19, 2007
Results First Posted : August 6, 2018
Last Update Posted : August 31, 2018
Information provided by (Responsible Party):
Richard Burt, MD, Northwestern University

January 18, 2007
January 19, 2007
June 20, 2017
August 6, 2018
August 31, 2018
February 2002
June 2016   (Final data collection date for primary outcome measure)
Survival [ Time Frame: Up to 5 years ]
  • Survival at 5 years
  • Osserman score
  • Quantitative Myasthenia gravis score (QMGS)
  • Improvement is defined as a 50% improvement in QMGS
  • Deterioration is defined as a 25% deterioration in QMGS
Complete list of historical versions of study NCT00424489 on Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
Hematopoietic Stem Cell Therapy for Patients With Refractory Myasthenia Gravis
Hematopoietic Stem Cell Therapy for Patients With Refractory Myasthenia Gravis

MG may be neonatal, congenital, or autoimmune. Neonatal MG arises from transplacental transfer of ACh receptor antibodies from a mother with autoimmune MG to the fetus. Neonatal MG resolves with post delivery clearance of maternal antibodies. Congenital MG results from a genetic defect in the ACh receptor. Patients with congenital MG do not have ACh receptor antibodies. Both neonatal and congenital MG are excluded from this study. Autoimmune MG, which is the most common form of MG, affects approximately 25,000 Americans. Like most autoimmune diseases, it is associated with particular HLA genotypes, has a female predominance, and environmental factors involved in breaking tolerance to the ACh receptor are unknown. Patients with refractory and severe autoimmune MG will be considered candidates for this study.

The purpose of this study is to assess the toxicity/feasibility (phase I) of autologous hematopoietic stem cell transplantation for refractory myasthenia gravis.

There will be no randomization in this study. All subjects who are determined to be eligible for the study treatment will receive high dose cyclophosphamide and ATG followed by infusion of autologous peripheral blood stem cells. The procedures the subject will undergo are as follows:

  1. Physician visit to determine potential eligibility for the study. Subjects will be evaluated by a transplant physician and a neurologist. They will have a complete physical examination and will provide a full medical history at these visits. The study will be described in detail by the transplant physician and nurse and the consent form will be provided to be taken home to read.
  2. Insurance verification. Subjects who remain interested in pursuing the study treatment and who have refractory myasthenia gravis will proceed to the insurance verification phase. Third party payment or self-pay must be verified before subjects can proceed.
  3. Consent form. Prior to proceeding, the appropriate signatures will be obtained on the consent form. Subjects will be given an opportunity to ask further questions of the attending physician and transplant nurse prior to signing the consent form.
  4. Pre-transplant testing. To determine final eligibility for the study, subjects will undergo a series of tests/procedures. These include: CXR; electrocardiogram; MUGA or echocardiogram; pulmonary function test; CT scan of the sinuses; CT scan of the chest to r/o thymoma; dental examination; urinalysis; and blood testing to include CBC, chemistries, liver and kidney function tests, coagulation studies, viral studies and, for females, a pregnancy test. All pre-transplant testing is routine medical testing done to verify diagnosis and to insure adequate organ function and absence of viral illnesses which would preclude a safe transplant course.
  5. Autologous peripheral blood stem cell collection. Subjects who are proceeding to transplant will undergo a routine procedure for the mobilization and collection of peripheral blood stem cells. This includes the administration of IV cyclophosphamide, given as an inpatient requiring an overnight stay, followed by the subcutaneous administration of G-CSF, to be self-administered as an outpatient. Approximately ten days after the administration of IV cyclophosphamide, the peripheral blood stem cells will be collected as an outpatient in the Blood Center. A pheresis catheter will be placed for this purpose on the first day of leukopheresis. Leukopheresis will be continued on a daily basis until an adequate number of peripheral blood stem cells have been collected (a maximum of four leukophereses may be performed). G-CSF will continue to be administered until leukopheresis is completed. The pheresis catheter will be discontinued when stem cell harvesting is completed. Processed cells will be frozen and stored until they are reinfused after the conditioning regimen.
  6. PICC line placement. Subjects will have a double lumen PICC line placed prior to the administration of study treatment for the administration of chemotherapy, IV fluids, blood products and the withdrawal of blood samples. The placement of a PICC line is a routine medical procedure.
  7. Study treatment. Subjects will undergo conditioning which will include four days of intravenous high dose cyclophosphamide and three days of intravenous anti-thymocyte globulin (ATG). Both cyclophosphamide and ATG are common immune suppressive agents. The previously collected peripheral blood stem cells will be reinfused following the completion of the conditioning regimen.
  8. Post-treatment follow-up. Subjects will have a history and physical by the transplant physician and neurologist at 3 months, 6 months, 12 months, and yearly for 5 years. In addition, routine urinalysis and blood testing will be performed at these same intervals to include CBC, chemistries, kidney and liver function tests.
Phase 1
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Myasthenia Gravis
  • Biological: Hematopoietic Stem Cell Transplantation
    Autologous Hematopoietic Stem Cell Transplantation
  • Drug: Cyclophosphamide
    Other Name: Cytoxan
  • Drug: ATG (rabbit)
  • Drug: Mesna
  • Drug: Methylprednisolone
  • Drug: G-CSF
Experimental: Hematopoietic Stem Cell Transplantation
Autologous Hematopoietic Stem Cell Transplantation will be performed after conditioning
  • Biological: Hematopoietic Stem Cell Transplantation
  • Drug: Cyclophosphamide
  • Drug: ATG (rabbit)
  • Drug: Mesna
  • Drug: Methylprednisolone
  • Drug: G-CSF
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
June 2016
June 2016   (Final data collection date for primary outcome measure)

Inclusion Criteria (Patients must fulfill all of the following)

  1. Established diagnosis of myasthenia gravis defined as clinical evidence of muscle weakness and fatigue ability and supported, an abnormal EMG-NCV repetitive nerve stimulation (or single-fiber EMG) or Lambert-Eaton Myasthenic Syndrome without evidence of malignancy.
  2. Ages 15-65 years.
  3. Positive antibody preferred (anti-AchR, MuSK, voltage gated calcium channel, anti-striational).
  4. Failure of thymectomy (except for Lambert-Eaton Myasthenic Syndrome).
  5. Failure anticholinesterase therapy, corticosteroids, and at least two of the following: azathioprine, cyclosporin, CellCept, cyclophosphamide, plasma exchange, or IVIG. Failure is defined as at least 6 months of the above drug therapy and an Osserman score of IIB, III, or IV and not clinically improving.

And at least one of the following:

  1. History of myasthenia crises (requiring mechanical ventilation) despite thymectomy and immunosuppressive therapy.
  2. Hospitalized or on ventilator support for myasthenia gravis within the last 18 months despite thymectomy and immunosuppressive therapy.
  3. Inability to maintain nutrition due to muscle weakness.
  4. A Karnofsky performance status of 70% or less (may or may not be able to care for self, but unable to carry on normal activity or unable to do active work).

Exclusion Criteria

  1. Significant end organ damage such as:

    1. LVEF <40% or deterioration of LVEF during exercise test on MUGA or echocardiogram.
    2. Untreated life-threatening arrhythmia, active ischemic heart disease or heart failure.
    3. DLCO < 40% of predicted value.
    4. Serum creatinine > 2.5 mg/dl.
    5. Liver cirrhosis, transaminases >3x of normal limits, or bilirubin >2.0 unless due to Gilberts disease.
  2. HIV positive.
  3. Uncontrolled diabetes mellitus, or any other illness that in the opinion of the investigators would jeopardize the ability of the patient to tolerate aggressive treatment.
  4. Prior history of malignancy except localized basal cell or squamous skin cancer. Other malignancies for which the patient is judged to be cured by local surgical therapy, such as (but not limited to) head and neck cancer, or stage I or II breast cancer, will be considered on an individual basis.
  5. Positive pregnancy test, inability or unable to pursue effective means of birth control, failure to willingly accept or comprehend irreversible sterility as a side effect of therapy.
  6. Psychiatric illness or mental deficiency making compliance with treatment or informed consent impossible.
  7. Inability to give informed consent
  8. Congenital myasthenia gravis
  9. Neonatal myasthenia gravis
  10. Osserman grade 1 or 2
  11. Pure red cell aplasia
  12. Any patient on insulin
Sexes Eligible for Study: All
15 Years to 65 Years   (Child, Adult, Older Adult)
Contact information is only displayed when the study is recruiting subjects
United States
Myasthenia Gravis Auto 2002
Not Provided
Plan to Share IPD: No
Richard Burt, MD, Northwestern University
Northwestern University
Not Provided
Principal Investigator: Richard Burt, MD Northwestern University and Northwestern Memorial Hospital
Northwestern University
August 2018

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP